Drug Discovery

Three companies – Cardinal Health, REGENXBIO, and Beacon Therapeutics – help us explore gene therapy development in the ophthalmic space

Machine learning has significant promise, but we should never overlook the importance of the human factor.

Can genetically engineering yeast be used to produce safe and scalable schizophrenia plant-inspired drugs?

Our roundup of some of our thoughtful and inspiring video interviews and roundtables from the past year.

Cerevel Therapeutics' Emraclidine - in development for schizophrenia and Alzheimer’s disease psychosis - yields positive results in phase Ib trial

Exploring the potential of hybrid peptide-DNA nanostructures and artificial life

How multi-omics and AI-driven target identification can drive the future of personalized medicine

A superbug vaccine could protect patients against multiple healthcare-associated infections at once

Researchers develop a new approach to mapping the individual heterogeneity of brain changes in mental disorders

In vivo animal models have brought much to the science behind the drug development industry, but how far behind are organ-on-a-chip models?